Document is current
Any future updates will be listed below
-
Authors
Schreiber, Katherine H.
Arriola Apelo, Sebastian I.
Yu, Deyang
Brinkman, Jacqueline A.
Velarde, Michael C.
Syed, Faizan A.
Liao, Chen-Yu https://orcid.org/0000-0002-6033-9415
Baar, Emma L.
Carbajal, Kathryn A.
Sherman, Dawn S.
Ortiz, Denise
Brunauer, Regina https://orcid.org/0000-0001-9384-5501
Yang, Shany E.
Tzannis, Stelios T.
Kennedy, Brian K.
Lamming, Dudley W. https://orcid.org/0000-0002-0079-4467
-
Funding
Funding for this research was provided by:
American Diabetes Association (1-16-PMF-001)
American Heart Association (17PRE33410983)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA014520)
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (UL1TR002373)
UW | School of Medicine and Public Health, University of Wisconsin-Madison
U.S. Department of Health & Human Services | NIH | National Institute on Aging (R01AG056771, R01AG062328)
Aeonian Pharmaceuticals
- License Information
-
More Information
Article History
Received: 25 August 2018
Accepted: 26 June 2019
First Online: 19 July 2019
Competing interests
: M.C.V. contributed to this manuscript while an employee of Aeonian Pharmaceuticals. S.T.Z. is the President and CEO of Aeonian Pharmaceuticals. B.K.K. is the Board Chair of Mount Tam Pharmaceuticals, which seeks to develop novel therapeutics to treat autoimmune diseases by modifying the mTOR pathway. D.W.L. has received funding from, and is a scientific advisory board member of, Aeonian Pharmaceuticals, which seeks to develop novel, selective mTOR inhibitors for the treatment of various diseases.
